Ignite Creation Date:
2024-05-06 @ 6:31 PM
Last Modification Date:
2024-10-26 @ 2:50 PM
Study NCT ID:
NCT05699044
Status:
RECRUITING
Last Update Posted:
2023-06-02
First Post:
2022-10-04
Brief Title:
Screening of ATTRwt in Patient With Advanced AV-Block Undergoing Pacemaker Implantation
Sponsor:
Steen Hvitfeldt Poulsen
Organization:
Aarhus University Hospital Skejby
Study Overview
Official Title:
Prevalence Characteristics and Prognosis of Transthyretin Amyloidosis in Patients With New-onset Advanced AV-block - A National Screening Study
Status:
RECRUITING
Status Verified Date:
2023-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
ATTRAB
Brief Summary:
The investigators will nationally investigate the prevalence of Transthyretin Amyloidosis wildtype ATTRwt in patients of 65 years with left ventricular hypertrophy who present with high degree atrioventricular block AV-block and are admitted for pacemaker implantation The investigators aim to characterize the group of patients with positive screening of ATTR and compare the ATTRwt disease stage at time of diagnosis for patients identified with ATTR at screening with a control group of routinely clinically diagnosed ATTRwt patients
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None